MannKind Corporation

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.23 ^USD	+1.20%		+1.20%	+16.21%

Mar. 26	MannKind CFO Binder to Retire in April, Names New CFO	MT
Mar. 26	MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024	CI

MannKind Corporation Appoints Steven B. Binder as Executive Vice President, Special Projects

March 26, 2024 at 04:05 pm EDT

MannKind Corporation announced that Steven B. Binder will retire from his position as Chief Financial Officer, effective April 22, 2024. Mr. Binder plans to remain at MannKind through the end of the year as Executive Vice President, Special Projects.

Latest news about MannKind Corporation

MannKind CFO Binder to Retire in April, Names New CFO	Mar. 26	MT
MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024	Mar. 26	CI
MannKind Corporation Appoints Steven B. Binder as Executive Vice President, Special Projects	Mar. 26	CI
MannKind Corporation Announces INHALE-3 Study?s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections and Insulin Pumps	Mar. 11	CI
Transcript : MannKind Corporation, Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Earnings Flash (MNKD) MANNKIND Reports Q4 Revenue $58.5M, vs. Street Est of $53.1M	Feb. 27	MT
MannKind Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
MannKind Corporation Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®	Feb. 15	CI
Transcript : MannKind Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 11:15 AM	Jan. 11
Transcript : MannKind Corporation - Special Call	Jan. 03
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday	Jan. 02	MT
MannKind Sells 1% Royalty on Tyvaso DPI Net Sales for Up to $200 Million	Jan. 02	MT
MannKind Restructures Supply Agreement with Amphastar Pharmaceuticals	Dec. 28	MT
Mannkind Insider Sold Shares Worth $801,928, According to a Recent SEC Filing	Dec. 18	MT
Oppenheimer Adjusts MannKind Price Target to $5.50 From $6.50, Maintains Outperform Rating	Nov. 14	MT
Transcript : MannKind Corporation, Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
MannKind Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Earnings Flash (MNKD) MANNKIND Reports Q3 Revenue $51.3M, vs. Street Est of $50.7M	Nov. 07	MT
MannKind Corporation Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living with Type 1 Diabetes	Nov. 06	CI
MannKind Receives US Patent for Clofazimine Inhalation Suspension to Treat Lung Disease	23-10-30	MT
Wedbush Initiates MannKind at Outperform With $10 PT; Says Orphan Lung Pipeline Presents Potential for Real Future Value-Creation, Optionality	23-10-10	MT
Transcript : MannKind Corporation Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 08:10 AM	23-09-13
HC Wainwright Adjusts Price Target on MannKind to $7.50 From $7, Keeps Buy Rating	23-08-14	MT
Sector Update: Health Care Stocks Mixed Premarket Tuesday	23-08-08	MT
MannKind Reports Q2 Breakeven, Revenue Rises	23-08-08	MT

Chart MannKind Corporation

Duration

Period

More charts

Company Profile

MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for MannKind Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.23 USD

Average target price

7.083 USD

Spread / Average Target

+67.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MANNKIND CORPORATION	+16.21%	1.15B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs